J&J prostate cancer therapy outperforms in real-world study

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) outperformed enzalutamide, a rival treatment marketed by Pfizer (PFE)/Astellas (OTCPK:ALPMF) as Xtandi.

Detailed data indicates that Erleada, an FDA-approved androgen receptor inhibitor led to a statistically significant benefit in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).

The study was based on electronic databases representing more than 3,700 patients who initiated Erleada or enzalutamide between December 16, 2018, and December 31, 2023.

According to its analysis, the mCSPC patients who received Erleada as their first androgen receptor inhibitor witnessed a 23% decline in their mortality risk at 24 months compared to those who started enzalutamide.

JNJ said the results were consistent with findings from its Phase 3 TITAN trial, which illustrated that Erleada, as part of a combination regimen with androgen deprivation therapy (ADT) caused a statistically significant benefit in overall survival compared to ADT alone.